We recently sat down with Rizwan Chaudhrey, a well-connected figure in the life science and pharmaceutical industries, to discuss the changes he has seen across the lab sector in recent years; how this has been impacted by COVID; and any new trends in lab informatics.
Rizwan, tell us about yourself and your work.
I’ve been involved in this field for a long time, building up a portfolio of connections across life science, biopharma, and pharma. I have worked alongside key opinion leaders for the past 8 years, including both members of the media and decision makers within the companies themselves. I have been involved in a myriad of different projects in the industry in that time, from event management to sales strategy. I now work across the whole value chain, aiming to connect and inform people through news, interviews and other forms of content.
I speak to people across all disciplines and roles, and generally host 2 types of interview. In-person interviews, usually at an industry event,where my interviewees generally talk about the company, what they’re showcasing at an event, and any product launches that might be coming up. Video interviews are often more topical, highlighting a specific subject or industry challenge.
During my time in this industry, I’ve visited many different eventsand spoken to hundreds of companies in this space, from large organisations to smaller start-ups. In the time I have been in the industry, lab informatics has changed a lot – it is very much an industry that keeps you on your toes!
What are some of the main trends you are seeing in the laboratory science sector?
Digitalisation is obviously a topic that is heavily discussed, certainly in the events I attend and the interviews I conduct. I think there’s been an interesting shift recently though. The whole industry thought that the COVID-19 pandemic would have a significant effect and drastically speed up the rate of adoption, like we’ve seen in other industries. Everything was going to move to the cloud, and remote access requirements led everyone to believe that we were going to move towards digitalisation at a rate of knots. While we are seeing increasing use of digitised systems, the shift has not been as quick or dramatic as people expected.
From my discussions with lab-based organisations, it appears that one of the big barriers to following through on digital transformation is not knowing where to start. At present, it doesn’t appear as though one vendor has “cracked it” and developed an all-in-one solution that addresses every lab’s needs – there are many different companies offering an array of services and solutions, which can be daunting for a lab-based organisation that is stuck somewhere on its digitalisation journey. For example, major vendors might offer solutions and software packages for their own instruments, but on another level you can look at platforms that focus on specific therapies – there are so many layers to the topic, which is why I believe there are still so many shows with exhibitors talking about what they can bring to the table.
AI/ML is a hot topic at present. Is this something that has come up in your interviews?
Certainly – you can’t avoid artificial intelligence as a topic at the moment! And you can understand why, it has plenty of advantages for labs.
AI can help labs not only generate insights from millions of cells, but also interpret that data and help identify the most valuable results. Machine learning (ML) also provides clear benefits in terms of equipment servicing, as ML-enabled instruments can help engineers and customers through self-diagnosis and troubleshooting. It also facilitates lab automation, through features like automatic refill notifications.
Are there any other trends you have identified?
Post-COVID, we’ve definitely seen a rise in collaboration. Organisations and scientists seem more willing than ever before to share information. We’re also seeing a shift towards automated processes in the lab, with systems using learnt information to lessen the need for human intervention.
In the current environmental climate, sustainability is naturally a big talking point too. Every company I speak to is keen to showcase their ESG practices, especially considering the impact the life science and pharmaceutical industry has on the environment.
Navigating the fog
We agree with Rizwan that the field of lab informatics is at an exciting crossroads. Still emerging from the madness of COVID, and with the growing promise of AI seeming more inevitable by the day, the industry is facing a period of unpredictability.
As scientists ourselves, the team at Scimcon is well-placed to help lab-based companies address their challenges. Find out more about how Scimcon can help you navigate the fog by visiting our website.
